Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

Brandon G. Busbee, Allen C. Ho, David M. Brown, Jeffrey S. Heier, Ivan J. Suñer, Zhengrong Li, Roman G. Rubio, Phillip Lai

Research output: Contribution to journalArticlepeer-review

339 Scopus citations

Fingerprint

Dive into the research topics of 'Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Medicine & Life Sciences